#1
|
|||
|
|||
Åñòü ëè äèâåðòèêóëû êèøå÷íèêà íà ÊÒ?
Óâàæàåìûå êîíñóëüòàíòû!
Ïàöèåíòêà 81 ãîäà, âðà÷-îôòàëüìîëîã. Çàáîëåëà 12 ëåò íàçàä. Îòìå÷àëèñü ïîäúåìû òåìïåðàòóðû ñ îçíîáîì, äî 38,0-39,0, â ïîñëåäíåå âðåìÿ è âûøå, ïðîäîëæèòåëüíîñòüþ 4-6-8 ÷àñîâ. Òåìïåðàòóðà ñàìà ïî ñåáå ñïàäàëà, ñëåäóþùèå äåíü- äâà îòìå÷àëàñü ñëàáîñòü. Äåíü äî ïîâûøåíèÿ òåìïåðàòóðû îòìå÷àåòñÿ ëîìîòà â òåëå, ìûøöàõ. Ñâåòëûå ïðîìåæóòêè ìåæäó ýòèìè «ïðèñòóïàìè» äîëãîå âðåìÿ áûëè 4-6-8 íåäåëü, ïîñëåäíèå 5 ìåñÿöåâ ñâåòëûå ïðîìåæóòêè ñîêðàòèëèñü äî íåñêîëüêèõ äíåé, áîëüíàÿ íå óñïåâàåò ïðèéòè â ñåáÿ. Çà ýòè ãîäû åå îáñëåäîâàëè â ãåìàòîëîãèè, èíôåêöèîííîì îòäåëåíèè. Íèêàêèõ äðóãèõ æàëîá íåò-êàøëÿ, îäûøêè.Òóáåðêóëåçà íå áûëî.Ëèìôîóçëû íå óâåëè÷åíû. Çàïîðîâ íåò. ÑÎÝ 20-24 ìì/÷àñ (íîðìà äî 15 ìì ÷àñ). Íèêîãäà íå áûëî áåëêà â ìî÷å. Âàæíî: çà ýòè 12 ëåò îíà íèêàêèõ ëåêàðñòâ íå ïðèíèìàëà, äàæå æàðîïîíèæàþùèå èçðåäêà, íî íåñêîëüêî ëåò íàçàä îäèí äîêòîð íàçíà÷èë åé èíúåêöèè àíòèáèîòèêà, íèêòî íå ïîìíèò êàêîãî, ïîñëå ýòîãî ïðèñòóïîâ íå áûëî öåëûé ãîä. Íåäàâíî îíà âûáðîñèëà âñå ïðîòîêîëû îáñëåäîâàíèé, ðàçîçëèâøèñü: «íó ðàç ó ìåíÿ âñå íîðìàëüíî...». Êàê ðàç ïîñëå ýòîãî ìåíÿ è ïðèãëàñèëè ê íåé íà äîì. Íåçàäîëãî äî ìîåãî îñìîòðà åé áûëè íàçíà÷åíû èíúåêöèè öåôòðèàêñîíà, íà ôîíå êîòîðûõ òåìïåðàòóðà íå ïàäàëà, íàîáîðîò äîøëà äî 39,9., èíúåêöèè ïðåêðàòèëè. Èç âîçìîæíûõ äèàãíîçîâ äëÿ ðàññìîòðåíèÿ ÿ îñòàíîâèëàñü íà äèâåðòèêóëèòå êèøå÷íèêà. Íàçíà÷èëà åé àëüôà-íîðìèêñ ïî 400 ìã 2 ð./ñ ïåðâûå 5 äíåé, ïî 200 ìã 2 ðàçà 2 äíÿ-èòîãî 7 äíåé, è ìåòðîíèäàçîë ïî 500 ìã 2 ðàçà 10 äíåé. Ïîñëåäíèé äåíü ïðèåìà ìåòðîíèäàçîëà âíîâü áûë "ïðèñòóï" ëèõîðàäêè äî 37,8 (âìåñòî îáû÷íûõ 38-39Ñ) ñ ïðîäðîìîé â âèäå ëîìîòû â òåëå çà äåíü äî "ïðèñòóïà", íî óæå áåç îçíîáà, ïðîäîëæèòåëüíîñòü 3,5 ÷àñà (ìåíüøå ÷åì äî ëå÷åíèÿ),ñâåòëûé ïðîìåæóòîê áåç ëèõîðàäêè áûë 10 äíåé (äîëüøå ÷åì ïîñëåäíèå ìåñÿöû), è íå áûëî òîé ðàçáèòîñòè ñëåäóþùèå äíè ïîñëå "ïðèñòóïà". Òî åñòü îíà ïåðåíåñëà ëåã÷å. Ó íåå ñîõðàíèëèñü ñíèìêè ÊÒ áðþøíîé ïîëîñòè áåç êîíòðàñòà. Óâàæàåìûå êîíñóëüòàíòû! 1. êàêîì íàïðàâëåíèè ìíå åå îáñëåäîâàòü? 2.Íóæíî ëè ïîâòîðíîå ÊÒ áðþøíîé ïîëîñòè (ñêîðåå âñåãî íóæíî), åñëè äà, îáúÿñíèòå ïîæàëóéñòà äåòàëè, êîòîðûå ÿ çàïðîøó ïðè íàïðàâëåíèè åå íà ÊÒ. 3. Êàêèå ó âàñ ìûñëè â ïëàíå äèôôåðåíöèàëüíî-äèàãíîñòè÷åñêîãî ïîèñêà, ïîæàëóéñòà ïîäåëèòåñü. Õîòåëîñü áû ïðîâåñòè öåëåíàïðàâëåííûå îáñëåäîâàíèÿ, íåîáðåìåíèòåëüíûå äëÿ ïàöèåíòêè. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#2
|
|||
|
|||
Øàõëà Þñèôîâíà, à íàöèîíàëüíîñòü êàêàÿ? ×àñîì íå ïåðèîäè÷åñêàÿ áîëåçíü?
__________________
Ñ óâàæåíèåì |
#3
|
|||
|
|||
Îæèäàëà ýòîò âîïðîñ, Þíîíà. Òàêóþ âåðñèþ âûäâèíóëè ðîäñòâåííèêè áîëüíîé, íåìåäèêè.Òåì áîëåå, ÷òî áîëüíàÿ ðîäîì èç Àðìåíèè, õîòü è àçåðáàéäæàíêà. Àðãóìåíòû ïðîòèâ:
1. Íåò àìèëîèäîçà ïî÷åê, áåç ëå÷åíèÿ çà ñòîëüêî ëåò ðàçâèëñÿ áû. 2. Íà÷àëî áîëåçíè â ïîæèëîì âîçðàñòå íåõàðàêòåðíî äëÿ ïåðèîäè÷åñêîé áîëåçíè, â 95% ñëó÷àåâ â âîçðàñòå äî 20 ëåò. Âïðî÷åì, ÿ íå âîçðàæàëà ïðîòèâ èõ æåëàíèÿ ñäåëàòü ãåíåòè÷åñêèé àíàëèç.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#4
|
|||
|
|||
Late-onset familial Mediterranean fever (FMF) : A subset with distinct clinical, demographic, and molecular genetic characteristics
Auteur(s) / Author(s) TAMIR N. (1) ; LANGEVITZ P. (1 2) ; ZEMER D. (1) ; PRAS E. (1 3) ; SHINAR Y. (1) ; PADEH S. (1 4) ; ZAKS N. (1 2) ; PRAS M. (1 2) ; LIVNEH A. (1 2) ; Affiliation(s) du ou des auteurs / Author(s) Affiliation(s) (1) Heller Institute of Medical Research, Sheba Medical Center, Tel-Hashomer and Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, ISRAEL (2) Department of Medicine F, Sheba Medical Center, Tel-Hashomer, ISRAEL (3) Department of Medicine C, Sheba Medical Center, Tel-Hashomer, ISRAEL (4) Department of Pediatrics, Sheba Medical Center, Tel-Hashomer, ISRAEL Résumé / Abstract To determine the prevalence and characterize demographic, clinical, and genetic features of familial Mediterranean fever (FMF) of late onset, all patients experiencing their first FMF attack at age 40 years or more were identified using the computerized registry of our FMF clinic, and then thoroughly interviewed and examined. The control group consisted of 40 consecutive FMF patients, who arrived at the FMF clinic for their regular follow-up visit and were 40 years of age or older at the time of the examination. The severity of the disease in patients and controls was determined using a modified score, developed previously. Mutational analysis in the FMF gene was performed using a commercial kit. Only 20 of 4000 (0.5%) patients had late-onset FMF. These patients were mostly men, of non-North African origin, P < 0.05 compared to controls. All had abdominal attacks and in most these were the only manifestation of their disease, P < 0.001. None had chronic or prolonged manifestations of FMF, for example, amyloidosis, chronic arthritis, or protracted myalgia, P < 0.001. The response to treatment was good despite using low colchicine dose, P < 0.05. The overall severity score indicated a mild disease, P < 0.001. Mutational analysis revealed absence of M694V homozygosity, P < 0.01, compared to our regular FMF population. We conclude that the onset of FMF in a late age defines a milder form of disease with typical clinical, demographic, and molecular genetic characteristics. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Äà, êñòàòè, à íà ÀÀ-àìèëîèäîç êèøêó ïðÿìóþ ùèïàëè? Êñòàòè, òóðêè òîæå áîëåþò ïåðèîäè÷åñêîé áîëåçíüþ. ß - çà ïðîâåäåíèå ãåíåòè÷åñêîãî àíàëèçà.
__________________
Ñ óâàæåíèåì |
#5
|
|||
|
|||
×òî çà ÀÀ-àìèëîèäîç? Ïî÷òè íèêàêèõ èññëåäîâàíèé íå ïðîâîäèëè, êðîìå ðóòèííûõ, è ÊÒ áðþøíîé.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#6
|
|||
|
|||
ÀÀ-àìèëîèäîç - âòîðè÷íûé ðåàêòèâíûé àìèëîèäîç, àìèëîèäîç â ðàìêàõ ïåðèîäè÷åñêîé áîëåçíè, à òàêæå àìèëîèäîç ïðè ñèíäðîìå Ìàêëà-Óýëüñà (ñåìåéíàÿ íåôðîïàòèÿ ñ êðàïèâíèöåé è ãëóõîòîé). À íà îñíîâàíèè ÷åãî áûë ñäåëàí âûâîä îá îòñóòñòâèè àìèëîèäîçà?
__________________
Ñ óâàæåíèåì |
#7
|
|||
|
|||
Îòñóòñòâèå ïðîòåèíóðèè.  ìî÷å çà 12 ëåò íå áûëî áåëêà- èíôîðìàöèÿ ñî ñëîâ ïàöåíòêè- âðà÷à, íî â ïðîãðàììå îáñëåäîâàíèÿ, êîòîðóþ ÿ õî÷ó êîíêðåòèçèðîâàòü ñ ïîìîùüþ ÄÊ, àíàëèç ìî÷è áóäåò åñòåññòâåííî. Íå ìîãó ïîõâàñòàòüñÿ, ÷òî õîðîøî çíàþ êëèíèêó àìèëîèäîçà äðóãèõ îðãàíîâ è ìîãó èõ ðàñïîçíàòü, ìîãó ïðåäïîëîæèòü òîëüêî, ÷òî äîëæíû áûòü íàðóøåíèÿ ôóíêöèè ýòèõ äðóãèõ îðãàíîâ.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#8
|
||||
|
||||
Ïðèâåäåííûé ñåìèëåòíåé äàâíîñòè ÊÒ æèâîòà íè÷åãî, êðîìå êàìíåé â æ¸ë÷íîì ïóçûðå è êèñòû ëåâîé ïî÷êè, íå ïðîäåìîíñòðèðîâàë.
 2002, ñóäÿ ïî èññëåäîâàíèþ, ïàöèåíòêà áûëà âåñüìà óïèòàííîé - èìååòñÿ ëè ïîòåðÿ âåñà? Åæåëè ÊÒ ïîâòîðèòü, òî íåîáõîäèìî êîíòðàñòèðîâàòü êèøå÷íèê, èñïîëüçîâàòü â/âåííûé êîíòðàñò è ñêåíèðîâàòü ãðóäíóþ êëåòêó (ñ ðåêîíñòðóêöèåé â ë¸ãî÷íîì è ìÿãêîòêàííîì îêíàõ), æèâîò è òàç. Õîòåëîñü áû ïîñìîòðåòü íà ÊÒ è êîñòíûé ðåæèì.  ïðèíöèïå, â äàííîì ñöåíàðèè ÿ áû íà÷àë ñ ðàäèîèçîòîïíîãî èññëåäîâàíèÿ. |
#9
|
|||
|
|||
Ñïàñèáî áîëüøîå êîíñóëüòàíòàì çà ïîìîùü.
Ïîòåðè âåñà çà ýòè 7 ëåò ìîæíî ñ÷èòàòü íå áûëî- òîëüêî 3-4 êã çà ïîñëåäíèå 5 ìåñÿöåâ â ñâÿçè ñ ó÷àùåíèåì "ïðèñòóïîâ" ëèõîðàäêè.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#10
|
|||
|
|||
íå êàæåòñÿ ëè Âàì, êîëëåãè, ÷òî ñòåíêà òîíêîãî êèøå÷íèêà ìåñòàìè óòîëùåíà?
È åùå. Âåðíî ëè ÿ ïîíèìàþ, ÷òî äðóãèõ æàëîá íåò: íàïðèìåð, áîëè â æèâîòå, íî÷íîé ïîò, ñâÿçàíà ëè ëèõîðàäêà ñ ïðèåìîì îïðåäåëåííîé ïèùè? |
#11
|
|||
|
|||
Äðóãèõ æàëîá íåò, åñòü òîëüêî ïðîäðîìà çà äåíü äî "ïðèñòóïà"-âÿëîñòü, ëîìîòà â òåëå, ìûøöàõ.
Ñêàçàëà èì î íåîáõîäèìîñòè ÊÒ îáñëåäîâàíèÿ â îáúåìå, ïðåäëîæåííîì óâàæàåìûì äîêòîðîì FRSM, ðîäñòâåííèêè ãîòîâû, ïàöèåíòêà ñàìà äîëæíà ñîãëàñèòüñÿ. Ïàöèåíòêà ïðîïèëà ëåâîôëîêñàöèí (òàâàíèê) 500 ìã/ñóò 10 äíåé. ×åðåç 2 äíÿ ïîñëå ïðåêðàùåíèÿ ïðèåìà òàâàíèêà îïÿòü áûë ïðèñòóï ñ ïîäúåìîì òåìïåðàòóðû äî 39,5.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#12
|
|||
|
|||
Èñòî÷íèê: Ð.Õýããëèí, "Äèô.äèàãíîñòèêà âíóòðåííèõ áîëåçíåé".
Ðåöèäèâèðóþùèå ëèõîðàäî÷íûå ñîñòîÿíèÿ. Ïî÷òè âñå ïðè÷èíû ëèõîðàäî÷íûõ ñîñòîÿíèé ìîãóò âåñòè èíîãäà ê ïîâòîðíûì ïðèñòóïàì ñ êîðîòêèìè èëè áîëåå äëèòåëüíûìè èíòåðâàëàìè. Îñîáåííî òèïè÷íû òàêèå ðåöèäèâèðóþùèå ïðèñòóïû äëÿ ñëåäóþùèõ çàáîëåâàíèé. à) Îïóõîëè. Õîðîøî èçâåñòåí òèï ëèõîðàäêè Ïåëü-Ýáøòåéíà (Pel-Ebstein) ïðè ëèìôîãðàíóëåìàòîçå; ïðè îïóõîëÿõ äðóãîãî ïðîèñõîæäåíèÿ âîëíîîáðàçíîå òå÷åíèå ëèõîðàäêè íàáëþäàåòñÿ ðåæå. (Øàõëà: äàåòñÿ òåìïåðàòóðíàÿ êðèâàÿ Pel-Ebstein, õàðàêòåð êðèâîé: çà 8 íåäåëü 2 ïîäúåìà ïðîäîëæèòåëüíîñòüþ íåäåëÿ, èíòåðâàë ìåæäó ïðèñòóïàìè 2 íåäåëè). Ïðè êàæäîì äèôôåðåíöèàëüíîì äèàãíîçå òàêèõ ñîñòîÿíèé íàäî ó÷èòûâàòü, ÷òî òóáåðêóëåç- ýòî âîëíîîáðàçíî ïðîòåêàþùàÿ áîëåçíü. Ðåöèäèâèðóþùèå ëèõîðàäî÷íûå ïðèñòóïû, ÷àñòî äëèòåëüíîñòüþ âñåãî â íåñêîëüêî ÷àñîâ,íî ñ íàñòîÿùèìè îçíîáàìè, íàáëþäàþòñÿ òàêæå ïðè çàêóïîðêå êàìíåì æåë÷íîãî ïðîòîêà. Åñëè ïîâûøåíèå òåìïåðàòóðû ñîïðîâîæäàåòñÿ êðàòêîâðåìåííîé æåëòóõîé èëè áîëÿìè â âåðõíåé ÷àñòè æèâîòà ñïðàâà, òî äèàãíîç ïðîñò. Åñëè æå ñèìïòîìû, óêàçûâàþùèå íà ýòó ëîêàëèçàöèþ, îòñóòñòâóþò, ÷òî áûâàåò îòíþäü íå ðåäêî, òî íàéòè ïðè÷èíó ïîâûøåíèÿ òåìïåðàòóðû î÷åíü òðóäíî
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |
#13
|
|||
|
|||
Óâàæàåìûå êîíñóëüòàíòû! Ðîäñòâåííèêàì ïîêà óäàëîñü óãîâîðèòü ïàöèåíòêó òîëüêî íà ÓÇÈ, âîò çàêëþ÷åíèå, ïðèñëàëè ìíå íà ýëåêòðîííûé àäðåñ:
Æåë÷íûé ïóçûðü – ñòåíêà óòîëùåíà, ïåðèïðîöåññ, â ïðîñâåòå äî 10 êîíêðåìåíòîâ ðàçìåðîì îò 11 äî 24 ìì. Ïå÷åíü – ðàçìåðû íå èçìåíåíû. Ýõîãåííîñòü óñèëåíà, ñòðóêòóðà çåðíèñòàÿ, êîíòóðû íåðîâíûå – õð.ãåïàòèò, öèððîòè÷åñêèå èçìåíåíèÿ, âíóòðèïå÷åíî÷íûå æåë÷íûå ïðîòîêè ðàñøèðåíû äî 6 ìì, õîëåäîõ ðàñøèðåí äî 19 ìì, â èíòåðïàíêðåàòè÷åñêîé ÷àñòè õîëåäîõà êîíêðåìåíò 23õ13 ìì. Ïîäæåëóäî÷íàÿ – ãîëîâêà 23 ìì, òåëî 13 ìì, õâîñò 24 ìì – óñèëåííîé ýõîãåííîñòè, êîíòóðû íåðîâíûå, ôèáðîç.
__________________
Èñðàôèëîâà Øàõëà Þñèôîâíà. Òåðàïåâò, ïóëüìîíîëîã. |